CDK4 and breast cancer: Our analysis of genetic and epigenetic alterations revealed that gene amplifications and heterozygous deletions were the most frequent copy number variations of CDK2 and CDK4 in breast cancer patients and were significantly (p<0.05) associated with poorer survival of breast cancer cohorts compared to cohorts with wild-type CDK2 and CDK4 (Figure 2A).